SCHEMBL13596757

SCHEMBL13596757

COc1ccc(-c2[nH]c(C(=O)NCCCCCC(=O)O)c(-c3ccccc3)c2C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
POLB P06746 2/20 0.43
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
PPARG P37231 1/20 0.42
KMT2A Q03164 1/20 0.42
NCOA2 Q15596 1/20 0.42
NCOA1 Q15788 1/20 0.42
HDAC1 Q13547 8/20 0.42
HDAC3 O15379 4/20 0.42
LTB4R Q15722 1/20 0.42
HDAC6 Q9UBN7 6/20 0.42
HDAC4 P56524 3/20 0.42
HDAC7 Q8WUI4 3/20 0.42
HDAC2 Q92769 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14025831 0.93 NPC1 (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL13596758 0.91 HDAC6 (0.52) HDAC1HDAC3HDAC6HDAC4HDAC7
SCHEMBL13597945 0.86 SMN1; SMN2 (0.41) ALDH1A1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL13598059 0.79 SMN1; SMN2 (0.41) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL14025830 0.78 LMNA (0.48) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL10064355 0.78 HDAC6 (0.48) HDAC1HDAC3HDAC6HDAC4HDAC7
SCHEMBL689775 0.78 HDAC6 (0.48) HDAC1HDAC3HDAC6HDAC4HDAC7
SCHEMBL14025824 0.78 KDM4E (0.52) ALDH1A1SMN1; SMN2MEN1HPGDKMT2A
SCHEMBL12791258 0.76 SMN1; SMN2 (0.48) ALDH1A1NPC1RAB9ASMN1; SMN2POLB
SCHEMBL12791142 0.76 SMN1; SMN2 (0.48) ALDH1A1NPC1RAB9ASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638550-B2 new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases. Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) (ES) 2009-12-29 US disclosed
US-20080262073-A1 Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (CNIO) (ES) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262073-A1 Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity HDAC1, HDAC11, HDAC5 ALDH1A1 469/4885NPC1 2578/4885RAB9A 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.